[Multimodal Treatment Strategies for Homebound Patients with Severe ME/CFS: A Scoping Review].
Mayer-Huber, Sandra, Kircher, Alissa, Eberhartinger, Maria et al. · Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) · 2024 · DOI
Quick Summary
This review looked at 14 published studies about ways to treat people with severe ME/CFS who are homebound or bedbound. The researchers found that the most helpful approaches were either home visits from healthcare providers or telemedicine (video/phone appointments). The studies highlighted that treatment works best when it's flexible, tailored to each person's daily needs, and includes family members in the care plan.
Why It Matters
Severely affected ME/CFS patients face unique barriers to receiving care, and this review identifies practical, accessible treatment delivery models (home visits and telemedicine) that could reduce patient burden. The emphasis on individualized, flexible care and family involvement reflects the specific challenges of managing a disease with unpredictable daily symptoms, offering evidence-based guidance for future service development and research design.
Observed Findings
Home visits (5 studies) and telemedicine (7 studies) were the predominant delivery formats for treating homebound ME/CFS patients.
Individualization and flexibility of treatment methods were emphasized in 8 studies as essential for addressing day-to-day symptom fluctuations.
Family involvement in treatment planning was explicitly described in 6 studies.
Outcome evaluation was inconsistent, with 7 studies using non-standardized questionnaires and no uniform assessment tools across publications.
Qualitative evaluations (n=3) consistently used thematic analysis methodology (Braun and Clarke).
Inferred Conclusions
Telemedicine and home-based care delivery models are feasible and appropriate alternatives to clinic-based treatment for severely affected ME/CFS patients.
Effective treatment of homebound ME/CFS patients requires flexibility to accommodate variable daily functional capacity rather than rigid, standardized protocols.
Family engagement in treatment planning may provide added clinical value for this patient population.
The evidence base for multimodal treatment in severe ME/CFS is sparse, and standardized outcome measures are needed for future research in this area.
Remaining Questions
What This Study Does Not Prove
This scoping review does not establish the efficacy of any specific treatment intervention—it only describes delivery methods and care structures reported in existing literature. The review cannot prove that home visits or telemedicine are more effective than in-person clinic visits, as most included studies lacked rigorous comparative designs. It also does not evaluate specific therapeutic content, only the organizational models in which care is delivered.
Tags
Phenotype:Severe
Method Flag:Weak Case DefinitionSevere ME Included
Which delivery model (home visits vs. telemedicine) produces better clinical outcomes, and does patient preference or disease severity affect this choice?
What specific components of multimodal treatment are most effective for homebound ME/CFS patients, and how should treatment be individualized based on symptom pattern or functional capacity?
How should family involvement be optimally structured, and what training or support do families need to effectively participate in care planning?
What standardized, validated assessment tools should be used to measure outcomes in homebound ME/CFS populations across future research studies?